RMTG reports Q3 sales up 52% YoY, achieves operational profitability, gross margin 75%

Regenerative Medical Technology Group Inc.

Sales rose 52% YoY to $986,308; gross profit margin reached 75% for Q3 2024.
Patient procedures revenue surged over 370% YoY, now 37% of revenue versus 12% last year.
Company achieved operational profitability, defined as revenue minus all operating expenses excluding interest and taxes.
Dubai clinic expected to launch next week; plans for a manufacturing facility in Cancun to produce exosomes and stem cells.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.